317-488-5500 
The recall of ranitidine was unusual among drug withdrawals. It was not triggered by a side effect that showed up in patients, and the FDA did not conclude the drug caused anyone’s cancer. What regulators found was that the pills were changing in the bottle, generating a probable carcinogen the longer they sat and the warmer they got.
That distinction shapes every legal question that follows, including who can be held responsible and whether a claim can still be brought at this point. Our Indianapolis dangerous drug attorneys at Christie Bell & Marshall evaluate these claims against Indiana’s product liability statutes rather than against headlines, and that review is free.
What Actually Happened, and When
The sequence is worth getting straight, because a lot of what circulates online compresses it into a single event.
In the summer of 2019, the FDA became aware of independent laboratory testing that found N-nitrosodimethylamine, or NDMA, in ranitidine. On September 13, 2019, the agency issued a statement alerting patients and health care professionals that NDMA had been found in samples of the drug. Individual manufacturer recalls followed through late 2019 and early 2020, beginning with a voluntary recall of Sandoz ranitidine capsules on September 24, 2019.
Then, on April 1, 2020, the FDA issued a withdrawal request for all ranitidine products, prescription and over-the-counter alike, effective immediately. That request removed the drug from American pharmacies entirely. Ranitidine has not been available for new or existing prescriptions or over-the-counter use since.
The agency was careful about what it was and was not saying. Janet Woodcock, then director of the FDA’s Center for Drug Evaluation and Research, noted that the agency “didn’t observe unacceptable levels of NDMA in many of the samples that we tested,” and explained the withdrawal on the basis that regulators could not know how or how long a given product had been stored.
What Ranitidine Was, and What NDMA Is
Ranitidine, sold under the brand name Zantac and as many generics, reduced stomach acid production. It was used for heartburn, acid reflux, gastroesophageal reflux disease, peptic ulcer disease, and Zollinger-Ellison syndrome, and it was one of the most widely taken drugs in the country for decades, available without a prescription.
NDMA is a contaminant, not an ingredient. It was never supposed to be in the product. The FDA describes it as a probable human carcinogen, meaning a substance that could cause cancer. It also appears at low levels in ordinary food and water, and the agency has been explicit that those low dietary levels would not be expected to raise anyone’s cancer risk, while sustained higher exposure may increase risk in humans.
The regulatory yardstick is a number worth stating precisely, because it is widely misreported. FDA’s acceptable daily intake limit for NDMA is 96 nanograms per day. It is a daily exposure ceiling, not a per-pill defect threshold, and a great deal of secondhand commentary gets that wrong. The agency’s NDMA testing record remains the authoritative source on what was measured and when.
Notably, FDA’s testing did not find NDMA in famotidine (Pepcid), cimetidine (Tagamet), esomeprazole (Nexium), lansoprazole (Prevacid), or omeprazole (Prilosec), which is why patients were directed toward those alternatives rather than away from acid reducers generally.
The Finding That Matters Legally
Buried in the April 2020 announcement is the fact that does the most work in a courtroom. FDA testing confirmed that NDMA levels increase in ranitidine even under normal storage conditions, increase significantly at higher temperatures including those the product may encounter during distribution and ordinary handling, and rise the longer it has been since the drug was manufactured.
Here is why that matters in Indiana specifically. Under IC 34-20-5-1, a product liability defendant gets a rebuttable presumption that the product was not defective and that it was not negligent, if before sale the product complied with applicable regulations approved by a federal or state agency, or conformed to the generally recognized state of the art. An FDA-approved drug walks into court with that presumption attached, and it is ordinarily the largest obstacle in a pharmaceutical case.
The storage finding is what a claimant would use to meet it. If the compound degrades into a probable carcinogen on the shelf, then the product that reached the consumer was not the product the agency evaluated, and the presumption is aimed at the wrong thing. The presumption is rebuttable by its terms, and this is the kind of evidence the statute contemplates rebutting it with.
What an Indiana Claim Has to Prove
Indiana does not treat every product theory the same way, which decides how one of these files gets built. IC 34-20-2-2 allows liability even where the seller exercised all reasonable care in manufacture and even where the injured person bought nothing from that seller. But it then requires that a claim based on a design defect, or on inadequate warnings or instructions, be proven by showing that reasonable care was not exercised by the manufacturer or seller, either in designing the product or in the warnings it gave.
For a drug case, that puts the emphasis on what the manufacturer knew and when. What did internal testing show about degradation? When did the company learn that heat and time raised NDMA levels? What did the labeling say about storage? Those questions are answered from company documents, not from the medical record, and they are the reason pharmaceutical claims are document-intensive and slow.
Causation is the second and harder half. A claim has to connect a specific person’s exposure to a specific diagnosis, which requires the medical records, a documented history of use, and expert testimony. This has been the contested battleground in ranitidine litigation nationally, and courts have scrutinized the epidemiological evidence closely. Anyone told their case is straightforward should treat that as a reason for more questions, not fewer, and a serious product liability evaluation will address causation honestly at the outset.
The Deadline That Decides Most Ranitidine Claims Now
For anyone reading this today, the threshold issue is not the science. It is time.
IC 34-20-3-1 sets two limits, and a claim must satisfy both. Suit has to be filed within two years of accrual. It also has to be filed no more than ten years after the product first reached a user or consumer, a repose period measured from the point of sale instead of the point of diagnosis. The statute applies regardless of minority or legal disability. A single exception softens the edge: when accrual falls in the window between the eighth and tenth year following that first delivery, the claimant gets two years from accrual to sue.
Apply that to this drug. Ranitidine left the American market on April 1, 2020, so no one has purchased it lawfully in the United States since that date. The repose clock on the last package lawfully sold therefore runs out in 2030, and for the far more common case of someone who took the drug for years before the recall, it has already expired or is close to it. A person diagnosed today whose ranitidine use ended in 2014 faces a repose problem no matter how strong the medical proof is.
That is not a reason to assume a claim is gone. Accrual dates in latent-disease cases are their own legal question, and the answer depends on facts specific to the person. It is a reason to have the dates evaluated now rather than later, because this analysis takes days and the alternative is discovering the answer after the window closes.
What Product Liability Claims Have Recovered
Defective product claims are among the largest recoveries Christie Bell & Marshall has secured, including $30,500,000 for a client trapped by a garage door that failed and $18,500,000 for a client who sustained a traumatic brain injury in a crash caused by a negligent truck driver. Further results are published on the firm’s case results page. Past results cannot guarantee what any individual case will produce, because every claim turns on its own facts.
Where a family lost someone, the claim proceeds as a wrongful death action brought by the personal representative of the estate, which carries its own filing requirements separate from the product liability deadlines above.
Talk to an Indianapolis Product Liability Lawyer
The useful question about ranitidine is not whether the recall happened. It is whether your dates still leave a claim open, and whether your medical records support the connection a court would require.
Bring CBM your prescription or pharmacy purchase history, the diagnosis and treatment records, and any remaining packaging. We will tell you plainly where the deadlines stand and whether the causation evidence in your situation is strong enough to be worth pursuing. You can reach CBM through our contact page for a free, confidential review.
FAQs About the Zantac and Ranitidine Recall
Did the FDA say Zantac causes cancer?
No. The FDA identified NDMA, a contaminant it describes as a probable human carcinogen, in ranitidine, and requested the drug’s removal because NDMA levels rise with age and heat and the agency could not verify how any given package had been stored. That is a different statement from a finding that the drug caused cancer in any particular person, and the distinction matters in court.
Is Zantac still on the market?
Ranitidine is not. Products now sold under the Zantac name use a different active ingredient. If you have old ranitidine at home, it should be disposed of rather than taken, and the FDA advised consumers to stop using it in April 2020.
What cancers have been alleged in ranitidine cases?
Claims have most often involved cancers of the digestive tract and several other organ systems, but the honest answer is that the alleged associations vary by case and have been vigorously disputed. Whether any particular diagnosis can be tied to ranitidine exposure is a question for the medical records and qualified experts, not for a list on a website.
Can I still file a claim in 2026?
It depends almost entirely on two dates: when you last took the drug, and when your condition was diagnosed. The ten-year repose period runs from the purchase, so long-term users who stopped well before the recall face the hardest timing problem. Anyone in that position should get the dates reviewed rather than assume either way.
What if my doctor kept prescribing it after the recall?
That raises a different claim. A prescriber who continued a withdrawn medication, or who failed to monitor a patient with a known exposure history, is a medical malpractice question governed by Indiana’s Medical Malpractice Act, with its own review panel process, damages cap, and a two-year deadline measured from the treatment itself.
Call 317-488-5500 or complete a Free Case Evaluation form
